Aktueile sicherheitsaspekte der therapie mit topischen calcineurin- inhibitoren

Translated title of the contribution: Current safety aspects of therapy with topical calcineurin inhibitors

Diamant Thaçi*, Rebekka Salgo

*Corresponding author for this work

Abstract

Atopic dermatitis is a chronic-inflammatory skin disease with relapsing and remitting course, with a high prevalence (10-20 %) in children of western countries. For many decades, topical corticosteroids have been the mainstay of therapy for atopic dermatitis. After the introduction of calcineurin-inhibitors as a corticosteroid-free alternative, expectations were high. After the black-box-warning of the FDA, regarding potential theoretical risk for developing neoplasia under the treatment with calcineurin inhibitors, an uncertainty occurred among patients and physicians.

Translated title of the contributionCurrent safety aspects of therapy with topical calcineurin inhibitors
Original languageGerman
JournalHaut
Volume18
Issue number1
Pages (from-to)36-40
Number of pages5
ISSN0938-2216
Publication statusPublished - 02.2007

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Fingerprint

Dive into the research topics of 'Current safety aspects of therapy with topical calcineurin inhibitors'. Together they form a unique fingerprint.

Cite this